Avid Bioservices, Inc.
CDMONASDAQHealthcare
$12.49
+$0.00(+0.00%)
Market Cap$798901617
P/E Ratio—
52W High$12.51
52W Low$5.9
Avid Bioservices, Inc. (CDMO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CDMO · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-04 | 2023-04 | 2022-04 | 2021-04 | 2020-04 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.14B | $0.15B | $0.12B | $0.10B | $0.06B |
| Cost of Revenue | $0.13B | $0.12B | $0.08B | $0.07B | $0.06B |
| Gross Profit | $0.01B | $0.03B | $0.04B | $0.03B | $0.00B |
| Gross Margin %(computed) | 5.23% | 21.09% | 30.64% | 30.57% | 6.59% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.03B | $0.03B | $0.02B | $0.02B | $0.01B |
| Total Operating Expenses | $0.03B | $0.03B | $0.02B | $0.02B | $0.01B |
| Operating Income | ($0.02B) | ($0.00B) | $0.01B | $0.01B | ($0.01B) |
| Operating Margin %(computed) | -13.35% | -1.75% | 9.08% | 9.31% | -17.73% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.03B) | $0.00B | $0.01B | $0.01B | ($0.01B) |
| Income Tax Expense | $0.11B | $0.00B | ($0.12B) | $0.00B | $0.00B |
| Net Income | ($0.14B) | $0.00B | $0.13B | $0.01B | ($0.01B) |
| Net Margin %(computed) | -100.60% | 0.38% | 106.75% | 11.70% | -12.15% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.23 | $0.01 | $2.08 | $0.06 | $-0.13 |
| Wtd Avg Shares | 0.06B | 0.06B | 0.06B | 0.06B | 0.06B |
| EBITDA | ($0.01B) | $0.01B | $0.02B | $0.02B | ($0.01B) |
| EBITDA Margin %(computed) | -8.21% | 7.31% | 16.64% | 16.37% | -12.35% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Avid Bioservices, Inc. data
About Avid Bioservices, Inc. (CDMO) Income Statement
Avid Bioservices, Inc. (CDMO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, CDMO reported revenue of $0.14B, gross profit of $0.01B (gross margin 5.23%), and net income of ($0.14B) — a net profit margin of -100.60%.
Frequently asked questions
CDMO · 4 questionsAvid Bioservices, Inc. (CDMO) reported revenue of $0.14B for 2024, down 6.3% year-over-year.
CDMO revenueCDMO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09